-
Otsuka buys startup Jnana, adding to uptick in private biotech M&A
01 Aug 2024 18:03 GMT
… might have been planning an initial public offering in a different market atmosphere … a clinical trial.
But with IPOs remaining difficult for many drug … the years. Just this week, PTC Therapeutics announced the submission of an …
-
Royalty Pharma Reports Second Quarter 2024 Results
08 Aug 2024 11:00 GMT
… of strong growth since our IPO. We also had a very … we expanded partnerships with Cytokinetics, PTC Therapeutics and Agios. In addition, reflecting … transactions include:
In June 2024, PTC Therapeutics exercised its option to sell …
-
PepGen Seeks $101 Million In U.S. IPO
02 May 2022 23:17 GMT
… developing related treatments include: PTC Therapeutics Sarepta Therapeutics Nippon Shinyaku … ;s enterprise value at IPO (excluding underwriter options) would … Listed bookrunners of the IPO are BofA Securities, SVB … the lead underwriter, and IPOs led by the firm …
-
PepGen Targets IPO For Duchenne Muscular Dystrophy Treatments
22 Apr 2022 20:46 GMT
… are developing related treatments include: PTC Therapeutics (PTCT) Sarepta Therapeutics (SRPT) … in total liabilities. PepGen IPO Details PepGen intends to … . Listed bookrunners of the IPO are BofA Securities, SVB … the lead underwriter and IPOs led by the firm …
-
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
24 Oct 2021 16:24 GMT
… (NYSE: BIO) (after the close)
PTC Therapeutics, Inc. (NASDAQ: PTCT) (after … (before the market open)
IPOs
IPO Pricing
Princeton, New Jersey-based … million shares in an IPO. The Marlborough, Massachusetts- … "CDLA."
IPO Quiet Period Expiry
Exscientia …
-
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
29 Jul 2021 12:56 GMT
… NASDAQ: LGND) (after the close)
PTC Therapeutics, Inc. (NASDAQ: PTCT) (after … Medical Systems (after the close)
IPOs
Nuvalent, Inc., (NASDAQ: NUVL … in cancer, priced its initial public offering of 9.75 million … diseases, priced its upsized IPO of 12.13 million …
-
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
25 Jul 2021 13:56 GMT
… (NASDAQ: LGND) (after the close)
PTC Therapeutics, Inc. (NASDAQ: PTCT) (after …
IPOs
IPO Pricing
Philadelphia, Pennsylvania-based Context Therapeutics, Inc. is planning an initial public offering … the ticker symbol OCEA.
IPO Quiet Period Expiry
CVRx, …
-
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
27 Jun 2021 17:22 GMT
… and a slew of biotech IPOs.
Here are the key … RP-L102 in Fanconi anemia
PTC Therapeutics, Inc. (NASDAQ: PTCT): … Rare Neurodegenerative Disease Drug
IPOs
IPO Pricing
Hong Kong-based … in an initial public offering. The company expects to price the IPO between …
-
Rx Rundown: Merck, Marea, Day One Biopharmaceuticals and more
21 Jun 2024 12:25 GMT
… nearly $115 million from its initial public offering.
UroGen Pharma aims to raise … of the Zantac cancer lawsuits.
PTC Therapeutics presented new biomarker data for …
-
Your Daily Pharma Scoop: Sanofi To Acquire Ablynx, PTC Therapeutics Announces Data, Lutathera Approved
30 Jan 2018 14:32 GMT
… also completed an U.S. IPO, which has helped in improving … in News: Analysis of PTCT PTC Therapeutics (PTCT) announced positive preliminary data …
About
© 1995-2024